Endocrinology Division, Hospital do Servidor Publico Estadual de São Paulo-IAMSPE, São Paulo, SP, Brazil.
Horm Metab Res. 2011 Mar;43(3):194-9. doi: 10.1055/s-0031-1271620. Epub 2011 Jan 31.
The chemokine CXCL10 plays an important role in Graves' disease (GD); however, data regarding the effectiveness of therapy are contradictory. Serum CXCL10 levels in 31 hyperthyroid patients were measured before and after establishing euthyroidism: 16 newly diagnosed GD patients received methimazole (MMI), 15 relapsed GD patients were treated with radioactive iodine (RAI), and 18 healthy subjects served as a control group. Baseline serum CXCL10 levels were higher than in controls (MMI group 144.0 ± 48.24, RAI group 156.3 ± 71.81 and control 71.32 ± 26.03 pg/ml; p < 0.01). In the MMI group, serum CXCL10 levels decreased following euthyroidism at 6 months (76.51 ± 22.06 pg/ml; p < 0.01) and 12 (76.42 ± 34.07 pg/ml; p < 0.01). In the RAI group, serum CXCL10 levels decreased after 3, 6, 9, and 12 months of RAI administration (82.37 ± 55.01, 66.35 ± 48.62, 68.76 ± 28.87, and 74.94 ± 49.74 pg/ml, respectively; p < 0.05). Elevated serum TRAb levels in the MMI group (33.15 ± 30.84) decreased at 6 months (14.64 ± 16.57 IU/l; p = 0.0070), whereas in the RAI group (44.61 ± 60.66 IU/l) they increased to a peak level at 6 months (66.40 ± 104.2 IU/l; p = 0.003), which was significantly higher than those of the MMI group, but were decreased at 12 months (28.91 ± 35.13 IU/l). Serum CXCL10 levels correlated with FT3 (r = 0.48, p < 0.0001), FT4 (r = 0.47, p < 0.0001) and TRAb (r = 0.37, p = 0.0014). In conclusion, these data show a relationship between serum CXCL10 and GD activity and suggest that a more complex mechanism is involved in the generation of the thyroid auto-antibodies TPOAb and TRAb.
趋化因子 CXCL10 在格雷夫斯病 (GD) 中发挥重要作用；然而，关于治疗效果的数据存在矛盾。在建立甲状腺功能正常后，测量了 31 例甲状腺功能亢进患者的血清 CXCL10 水平：16 例新诊断的 GD 患者接受甲巯咪唑 (MMI) 治疗，15 例复发性 GD 患者接受放射性碘 (RAI) 治疗，18 例健康受试者作为对照组。与对照组相比，基线时血清 CXCL10 水平升高（MMI 组 144.0 ± 48.24、RAI 组 156.3 ± 71.81 和对照组 71.32 ± 26.03 pg/ml；p < 0.01）。在 MMI 组中，血清 CXCL10 水平在 6 个月（76.51 ± 22.06 pg/ml；p < 0.01）和 12 个月（76.42 ± 34.07 pg/ml；p < 0.01）时随甲状腺功能正常而降低。在 RAI 组中，血清 CXCL10 水平在接受 RAI 治疗 3、6、9 和 12 个月后降低（82.37 ± 55.01、66.35 ± 48.62、68.76 ± 28.87 和 74.94 ± 49.74 pg/ml，分别；p < 0.05）。MMI 组中升高的 TRAb 水平（33.15 ± 30.84）在 6 个月时（14.64 ± 16.57 IU/l；p = 0.0070）下降，而 RAI 组（44.61 ± 60.66 IU/l）在 6 个月时升至峰值（66.40 ± 104.2 IU/l；p = 0.003），明显高于 MMI 组，但在 12 个月时（28.91 ± 35.13 IU/l）下降。血清 CXCL10 水平与 FT3（r = 0.48，p < 0.0001）、FT4（r = 0.47，p < 0.0001）和 TRAb（r = 0.37，p = 0.0014）相关。综上所述，这些数据显示血清 CXCL10 与 GD 活动之间存在关联，并表明在甲状腺自身抗体 TPOAb 和 TRAb 的产生中涉及更复杂的机制。
